Lexaria Bioscience Corp. (NASDAQ:LEXX) announced positive findings from its Phase 1b clinical study GLP-1-H24-4, a 12-week chronic trial focusing on its DehydraTECH™ (DHT) delivery platform in comparison to the Rybelsus® control arm.
The study, recently completed in Australia, explored four DHT arms and examined secondary efficacy, body composition, blood pressure, and pharmacokinetic parameters, providing crucial insights that may guide future research and development efforts.
Richard Christopher, CEO of Lexaria, expressed enthusiasm about the results, noting, "This adds to a growing dataset that highlights the potential benefits of our DehydraTECH platform. Clinical data is essential at this stage, and we are excited for the directions our research is taking into 2026 and beyond."
At the 16-week mark, there were no significant differences in mean fasting glucose, cholesterol, and LDL cholesterol between the DHT arms and the Rybelsus® control group.
In terms of body composition, the DHT-semaglutide group showed a modest reduction in fat mass (-1.08 kg) and total mass (-1.40 kg), with minimal reduction in lean mass (-0.41 kg), compared to more significant reductions in the Rybelsus® group.
The study also observed that the DHT-CBD arm, which was not designed as an efficacy endpoint, achieved notable reductions in blood pressure, which was of particular interest given the participants were not required to be hypertensive.